Patent ID: 9018245
Filing Date: 2015-04-28
Classification: A61K,A61P,C12N,G01N

Abstract:
1. A method of screening for a substance inhibiting that inhibits CD22 expression, comprising: (a) contacting said substance with cultured IgM or IgD positive naive B cells; (b) measuring CD22 expression in said naïve B cells following said contacting step; (c) comparing CD22 expression in step (b) with CD22 expression in control IgM or IgD positive naïve B cells; and (d) determining whether said substance inhibits CD22 expression in said cultured IgM or IgD positive naive B cells relative to the control naïve B cells; and (e) selecting the substance as a substance that promotes an early stage immune response based on said inhibition of CD22 expression in said cultured IgM or IgD positive naïve B cells relative to the control naïve B cells.